Pharmaceuticals

Hinova

Hinova released FY2026 Q1 earnings on April 24 After-Market (BJT), actual revenue CNY 26.03 M, actual EPS CNY -0.3

Hinova to Release FY2026 Q1 Earnings on April 25 After-Market BJT

Hinova to Release FY2025 Annual Earnings on April 25 During-Market (BJT), Forecast Revenue CNY 58M, EPS CNY -1.49

Hinova released FY2025 annual earnings on February 27 During-Market (BJT), actual revenue CNY 20.47 M (forecast CNY 58 M), actual EPS CNY -1.39 (forecast CNY -1.49)

Hinova released FY2025 Q4 earnings on February 27 During-Market (BJT), actual revenue CNY -2.882 M, actual EPS CNY -0.3907

Hinova released FY2025 9 Months earnings on October 30 After-Market (BJT), actual revenue CNY 23.35 M, actual EPS CNY -1.0007

Hinova released FY2025 Q3 earnings on October 30 After-Market (BJT), actual revenue CNY 10.18 M, actual EPS CNY -0.3808

Hinova FY2025 Q3 Earning Release on October 31, 2025 After-Market (BJT)

Hinova released FY2025 Semi-Annual earnings on August 13 After-Market BJT, actual revenue CNY 13.17 M, actual EPS CNY -0.62

Hinova released FY2025 Q2 earnings on August 13 After-Market BJT, actual revenue CNY 13.17 M, actual EPS CNY -0.2998

Hinova to Release FY2025 Semi-Annual Earnings on August 14, 2025 (BJT)

Hai Chao Pharmaceutical Undergoes Block Trades and Shareholding Changes

HaiChuang Pharmaceutical's Shareholder's Reduction Hits 1% Threshold

HaiChuang Pharmaceutical's Anti-Cancer Drug Issues First National Prescription

Huichuang Pharmaceutical Accepts Institutional Research on Sales Strategy

HC-Precision Medicine’s Deuterated Enzalutamide Capsule Approved for Market

Huichuang Pharmaceutical's Self-developed New Drug Hainana Approved by National Medical Products Administration

Yingchuang Power plans to 减持 HaiChuang Pharmaceutical's stock

Hinova released FY2025 Q1 earnings on April 25 After-Market (BJT), actual revenue CNY 0, actual EPS CNY -0.32

Hinova FY2025 Q1 Earnings Release Scheduled for April 26, After-Market BJT

688302

600513

09992

688136

000813

Innovative drug concept stocks showed active performance, with JLPC touching the daily limit, Menovo hitting 5 daily limits in 6 days, and Kingchem, Hinova, SDKX, DEZHAN HEALTHCARE, and WBDE following suit. In morning trading, the military industry sector surged; Jianshe Industry hit 2 daily limits in 4 days, while North Long Dragon, GreatWall Military, Jieqiang Equipment, FIRMACO, and Guoke Group climbed

- On March 27, A-shares opened low but recovered slightly, with key indices reducing losses; various sectors like CRO and innovative pharmaceuticals showed strength, while memory and optical communication hardware adjusted.  
- The bond market saw a downturn, with government bond futures declining, and most domestic commodity futures also fell, particularly for indexes and certain metals.  
- Lithium battery material stocks remained strong, with significant production increases noted for energy storage cells, while innovative drug stocks and military sectors exhibited particular upward movements amidst geopolitical tensions affecting oil prices.

Wallstreetcn

JLPC

POP MART

Menovo

SDKX

DEZHAN HEALTHCARE

WBDE

North Long Dragon

Guoke Group

Jieqiang Equipment

Kingchem

FIRMACO

GreatWall Military

Shanghai Composite Nears Positive Territory, Pharmaceutical Stocks Surge, Computing Hardware Stocks Continue to Adjust, HSI Fluctuates Higher, New Consumption Concept Stocks Rebound, POP MART Rises 2%

512290

159992

159929

516930

589720

510660

Shineway Profit Rises Despite Revenue Slump as TCM Sector Resets

Tip Ranks

Guotai CSI Bio-medicine ETF

Yinhua CSI Innovative Drugs Industry ETF

China Universal 800 Health Care ETF

Bosera Hang Seng Health Care ETF(QDII)

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

SHINEWAY PHARM

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Minsheng Royal CSI Biotechnology Theme ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

SINOPHARM(CNCM LTD)

Guotai SSE STAR Brand Name Drug ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

E Fund CSI 300 Health Care ETF

ChinaAMC SSE Health Care ETF Initiating Fund

Penghua CSI HK Connect Health Care Composite ETF

ChinaAMC SSE STAR Biology and Medicine ETF

E Fund Hang Seng SCHK Innovative Drug ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Shineway Profit Rises Despite Revenue Slump as TCM Sector Resets

03887

HashKey Sets March 2026 Board Meeting to Approve 2025 Final Results

HASHKEY HLDGS

HashKey Sets March 2026 Board Meeting to Approve 2025 Final Results

According to statistics, excluding the financial industry, the food and beverage industry had a gross profit margin of 51.41% in the first half of 2023, continuing to rank first. The beauty and personal care and media industries ranked second and third, respectively. The pharmaceutical and biotechnology and computer industries had outstanding individual stock performances, with Hinova ranking first with a gross profit margin of 99.52%, and a total of 27 individual stocks had gross profit margins exceeding 90%

Zhitong

Two major industries' stocks cluster in the gross margin ranking, with 27 stocks having a gross margin exceeding 90% in the first half of the year

000989

688331

09995

The concept of innovative drugs has rebounded, with JZT hitting the daily limit, Hinova, RemeGen, and Shenzhou Cell rising over 10%, while Fuyuan Pharmaceutical, Kangchen Pharmaceutical, Guangshengtang, and Nuo Cheng Jianhua are among the top gainers

RemeGen

REMEGEN

The concept of innovative drugs fluctuates and rebounds, JZT hits the limit up

Hinova released its 2025 semi-annual report, with revenue of 13.17 million yuan, a year-on-year increase of 11,899.08%. The net loss attributable to the parent company was 61.85 million yuan, and the net profit excluding non-recurring items was a loss of 73.01 million yuan, with basic earnings per share of -0.62 yuan. The significant revenue growth was mainly due to the launch of the new drug deuterated enzalutamide soft capsules, with sales revenue reaching 13.0688 million yuan

Hinova Pharmaceuticals released its semi-annual performance, with a net loss attributable to the parent company of 61.85 million yuan

000513

01513

300723

Caitong Securities released a research report indicating that there are many gout patients in China, accounting for over 30% of the global total. In terms of uric acid-lowering treatment, the clinical research competition for URAT1 inhibitors is intense, while acute phase relief treatment focuses on IL-1β inhibitors. It is recommended to pay attention to related companies, including ApicHope, LIVZON GROUP, and Hinova. Gout treatment is divided into acute and stable phases, with acute phase treatment primarily using colchicine and non-steroidal anti-inflammatory drugs, while uric acid-lowering treatment includes various medications

LIVZON GROUP

LIVZON PHARMA

ApicHope

Caitong Securities: Multiple new innovative drugs have emerged in the field of gout, focusing on companies related to uric acid reduction and acute phase relief treatment

603229

603716

Innovative drug concept stocks collectively fell, Ausun Pharm hit the limit down, SDKX dropped over 10%, Thalys, DEZHAN HEALTHCARE, and Hinova had significant declines

Ausun Pharm

Thalys

Innovative drug concept stocks collectively declined, Ausun Pharm hit the limit down

300674

605488

000729

In the past two days, a total of 81 companies announced institutional research records, among which 26 companies were researched by more than 10 institutions. The company with the most participating research institutions is Fulai New Material, with 93 institutions conducting research, followed by Yanjing Brewery, with 81 institutions participating in the research. Yusys Technologies and Hinova also had 50 or more institutions conducting research

Yusys Technologies

Fulai New Material

Yanjing Brewery

In the past two days, 26 companies have been clustered for institutional research

According to the announcement from Hinova, the company's independently developed Class 1 new drug Haina'an® (generic name: Deutetrabenazine soft capsules) has been approved for marketing by the National Medical Products Administration. It is used for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) who have experienced disease progression after receiving abiraterone acetate and chemotherapy, and who have not previously received novel androgen receptor inhibitors

Hinova: The new drug application for Dronedarone soft capsules has been approved

Hinova(688302.SH)

Shanghai Composite Nears Positive Territory, Pharmaceutical Stocks Surge, Computing Hardware Stocks Continue to Adjust, HSI Fluctuates Higher, New Consumption Concept Stocks Rebound, POP MART Rises 2%

Shineway Profit Rises Despite Revenue Slump as TCM Sector Resets

HashKey Sets March 2026 Board Meeting to Approve 2025 Final Results

Two major industries' stocks cluster in the gross margin ranking, with 27 stocks having a gross margin exceeding 90% in the first half of the year

The concept of innovative drugs fluctuates and rebounds, JZT hits the limit up

Hinova Pharmaceuticals released its semi-annual performance, with a net loss attributable to the parent company of 61.85 million yuan

Caitong Securities: Multiple new innovative drugs have emerged in the field of gout, focusing on companies related to uric acid reduction and acute phase relief treatment

Innovative drug concept stocks collectively declined, Ausun Pharm hit the limit down

In the past two days, 26 companies have been clustered for institutional research

Hinova: The new drug application for Dronedarone soft capsules has been approved